Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolaus Schultz

Showing results (161-170 of 310) with videos related to

Pageof 31
Sort By:
Cancer Cell|March 6, 2018
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial SarcomaAna Banito, Xiang Li, Aimée N Laporte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2024
A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome ClassifierYi Song, Thomas Boerner, Esther Drill, et al.
Cancer Medicine|September 11, 2019
Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusionJ Joshua Smith, Walid K Chatila, Francisco Sanchez-Vega, et al.
Cancer Cell|December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancerLianjie Li, Chuan Shen, Eijiro Nakamura, et al.
Nature Genetics|December 1, 2009
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah, Barry S Taylor, Shasha Meng, et al.
Cancer Cell|August 16, 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progressionMuhan Chen, Christopher P Pratt, Martha E Zeeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerIan J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Annals of Surgical Oncology|January 4, 2020
Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
Pageof 31

Showing results (161-170 of 310) with videos related to

Sort By:
Pageof 31
Cancer Cell|March 6, 2018
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial SarcomaAna Banito, Xiang Li, Aimée N Laporte, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2024
A Novel Approach to Quantify Heterogeneity of Intrahepatic Cholangiocarcinoma: The Hidden-Genome ClassifierYi Song, Thomas Boerner, Esther Drill, et al.
Cancer Medicine|September 11, 2019
Genomic stratification beyond Ras/B-Raf in colorectal liver metastasis patients treated with hepatic arterial infusionJ Joshua Smith, Walid K Chatila, Francisco Sanchez-Vega, et al.
Cancer Cell|December 17, 2013
SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancerLianjie Li, Chuan Shen, Eijiro Nakamura, et al.
Nature Genetics|December 1, 2009
Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesSelvaraju Veeriah, Barry S Taylor, Shasha Meng, et al.
Cancer Cell|August 16, 2011
Identification of PHLPP1 as a tumor suppressor reveals the role of feedback activation in PTEN-mutant prostate cancer progressionMuhan Chen, Christopher P Pratt, Martha E Zeeman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancerIan J Majewski, Paolo Nuciforo, Lorenza Mittempergher, et al.
Nature Genetics|July 18, 2018
Genome doubling shapes the evolution and prognosis of advanced cancersCraig M Bielski, Ahmet Zehir, Alexander V Penson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2014
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapyMartin H Voss, A Ari Hakimi, Can G Pham, et al.
Annals of Surgical Oncology|January 4, 2020
Correction to: Rates of TP53 Mutation are Significantly Elevated in African American Patients with Gastric CancerElke J A H van Beek, Jonathan M Hernandez, Debra A Goldman, et al.
Pageof 31